NCT00357318View on ClinicalTrials.gov

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2012

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

sunitinib malate

Given PO

BIOLOGICAL

bevacizumab

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

44106

Case Western Reserve University, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00357318 - Bevacizumab and Sunitinib in Treating Patients With Solid Tumors | Biotech Hunter | Biotech Hunter